“I joined RareCan to support research into my extremely rare and highly aggressive subtype of uterine cancer.”
A-Z Rare Cancer Directory & Clinical Trial Support
Explore our A-Z directory of rare and less common cancers to find dedicated clinical trial information and genomic testing support. While we specialise in supporting patients with rarer histological subtypes, we believe every cancer is unique. Select your diagnosis below to discover how our expert navigators can help you find your next treatment option.
Browse by cancer name
Explore cancer types by name. Use the A–Z list below to find information about your cancer diagnosis and related conditions.
RareCan has over 3,000 members, here’s what some of them say.
Whether you’re looking for clinical trials, exploring cancer research studies, or simply wanting to understand your cancer diagnosis or treatment options better, these RareCan resources are here to guide you during your cancer treatment journey.
— Lindy
RareCan Member
“I joined RareCan to get action and support and research on rare cancers”
— Steve
RareCan Member
“I joined RareCan because they have the solution to the challenges faced within rare cancer research.”
— Dave
RareCan Member
“I joined RareCan as it may help other people in the future.”
— Wayne
RareCan Member
“If my husband was alive today, he would encourage people to take part in research as you never know if you will ever need it in the future.”
— Wendy
How can RareCan help you?
Expert guidance through the complexity of clinical trials.
Finding the right clinical trial is overwhelming. The jargon is heavy, criteria are strict, and doctors rarely have time to explore every option. RareCan provides a dedicated, expert service to cut through the noise.
Choose the level of support you need to get started:
Trial Navigation Call
Understand clinical trials and whether / when they might be an option for you £50
- 30 minute call with an experienced Trial Navigator
- Review your current situation and treatment
- Discuss whether / when trials might be an option for you
- Explanation of UK cancer trials and how they work
- £50 credit towards Personalised Report or InsightDecode
InsightDecode
Advanced trial matching using your existing genetic test results £250
- Everything in the Personalised Report
- Bespoke trial matching based on your specific genetic biomarkers
- Translation of your existing genetics report into plain English
- Expert review of treatment and trial options
Explore our Insight liquid biopsy options
Insight CSB - Comprehensive Genomic Profiling of Solid Tumours from Blood
What it is:
The CSB test analyses a broad range of cancer-related genes from a blood sample to provide a detailed understanding of your tumour biology – with results written for people, not just specialists.
What it is for:
Designed for people who want the fullest possible insight, particularly when:
- Standard treatment options have been exhausted
- You want to explore what else might exist beyond routine care
- You want a report you can actually use in conversations about next steps
Why it is different:
- Broader gene coverage than other leading market tests
- UK-focused clinical trial matching, explained in context
- A clear, human-readable summary – not just technical findings
Genes included:
The CSB panel analyses 523 genes for SNVs/InDels, 59 genes for CNVs, and 23 genes for fusions, covering the most frequently referenced and clinically relevant in rarer solid tumours, including TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, MMR genes, NTRK and more.
Additional biomarkers:
- Microsatellite instability (MSI), a feature of how DNA repair works
- Tumour mutational burden (TMB), a measure of how many mutations are present
- Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour
Price: £3,250
Get more information about the Insight CSB test
Book a free call to find out whether the Insight CSB is right for you
Ready to book an Insight CSB test? Click here to order a test today
Insight PCB - Precision Genomic Profiling of Colorectal Cancer from Blood
What it is:
The Insight PCB test focuses on the critical BRAF and MAPK/ERK signalling pathways, offering comprehensive coverage of RAS and RAF drivers, alongside essential tumour suppressors, mismatch repair (MMR) genes, and actionable fusions. The test is done from a blood sample to provide a detailed understanding of your tumour biology – with results written for people, not just specialists.
What it is for:
The test is designed to support therapeutic decision-making, including the selection of:
- Anti-EGFR Therapies (e.g. Panitumumab, Cetuximab)
- BRAF Inhibitor Combinations (e.g. Encorafenib + Cetuximab)
- Immune Checkpoint Inhibitors (e.g. Pembrolizumab, Nivolumab)
- Targeted Therapies (e.g. HER2, TRK, MET inhibitors)
Why it is different:
- Specifically designed to cover the most important genes and biomarkers for colorectal cancer patients
- UK-focused clinical trial matching, explained in context
- A clear, human-readable summary – not just technical findings
Genes included:
AKT, ALK, APC, BRAF, EGFR, ERBB2, FBXW7, FGFR2, FGFR3, HRAS, KRAS, MAP2K1, MAP2K2, MAPK1, MET, MLH1, MSH2, MSH6, NRAS, NTRK1, NTRK2, PIK3CA, PMS2, POLD1, POLE, PTEN, RET, ROS1, SMAD4, TP53, VEGF-A.
Additional biomarkers:
- Microsatellite instability (MSI), a feature of how DNA repair works
- Tumour mutational burden (TMB), a measure of how many mutations are present
- Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour
Price: £2,500
Get more information about the Insight PCB test
Book a free call to find out whether the Insight PCB is right for you
Ready to book an Insight PCB test? Click here to order a test today
Insight TSB - Targeted Genomic Profiling of Solid Tumours from Blood
What it is:
The TSB test analyses a targeted set of cancer-related genes from a blood sample, providing clear insight into tumour changes over time, with the same emphasis on clarity and UK trial context.
What it is for:
Designed for people who:
- Wish to track disease progression or molecular changes over time, or
- Want more affordable access to key tumour genomics to explore what else might exist beyond routine care
Why it is different:
- Broader coverage and better sensitivity than comparable tests
- UK-focused clinical trial matching, explained in context
- A clear, human-readable summary – not just technical findings
Genes included:
The TSB test detects 118 cancer-related genes, covering the most frequently referenced and clinically relevant in rarer solid tumours, including TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, MMR genes, NTRK and more.
Additional biomarker:
- Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour
Price: £2,200
Get more information about the Insight TSB test
Book a free call to find out whether the Insight TSB is right for you
Ready to book an Insight TSB test? Click here to order a test today
The Journal
Discover the expert perspectives, the clinical insight, the cancer research breakthroughs, and the real experiences from the RareCan community.
Supported by
Our Partners
Regulatory Compliance
